Lonza, Inc.

Software

Lonza Chooses Emerson's Syncade(TM) Smart Operations Management Suite for Existing Biopharmaceutical Facility

Syncade(TM) software integrated with PlantWeb® architecture to optimize performance of Large Scale-Cell Culture facility in Portsmouth, New Hampshire AUSTIN, TEXAS (September 15, 2009) -- Global biopharmaceutical manufacturer Lonza has selected Emerson Process Management to provide manufacturing operations management software to further enhance the strong performance of plant operations at...

Read More »
Company News

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna's Vaccine (mRNA-1273) Against Novel Coronavirus

   Collaboration goal to enable manufacturing of up to 1 billion doses per year •  Technology transfer expected to begin in June 2020 •  First batches of mRNA-1273 expected to be manufactured at Lonza U.S. in July 2020 •  Collaboration leverages Lonza’s worldwide expertise in technology transfer and manufacturing     Quote from Stéphane Bancel, Chief Executive Officer, Moderna:...

Read More »
Company News

Lonza Selected as a Finalist for Innovation Award at 2020 World of Wipes® (WOW) International Conference

Lonza was selected as a finalist for the World of Wipes Innovation award As one of three finalists, Lonza will present their NUGEN® NR Disinfectant Wipes at the World of Wipes International conference on 22-25 June 2020. Quote from Dave Rousse, INDA President: “While cognizant of the evolving COVID-19 situation, we are proceeding with plans for an exceptional event in late June including three...

Read More »
People in the News

Lonza Group Strengthens its Executive Committee with the Appointment of New CHRO

Caroline Barth appointed as CHRO and member of the Lonza Group Executive Committee Caroline brings a wealth of experience from a 25-year multinational career with specific expertise in culture transformation and diversity Recent positions include Global Head of Human Resources, Novartis Pharma, and Global Head ad interim of Novartis Pharma Strategy (previously Global HR Head, Technical...

Read More »
People in the News

Board Announcement

Basel, Switzerland, 12 November 2019 – – Lonza announced today that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found. Marc will stay until January 2020 to ensure a smooth hand-over. In...

Read More »
Company News

Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC

• Expansion to bioconjugation facility in Visp, Switzerland to meet increasing clinical, launch and commercial market demand • Facility recently approved for the commercial manufacture of third antibody-drug-conjugate (ADC) • All ADC elements currently available under a single quality system in the Lonza network and from 2020 at a single site Quote from Karen Fallen, Head of Mammalian...

Read More »
Company News

Lonza Provides Adjusted Mid-Term Guidance and Emphasizes Growth Along the Healthcare Continuum®

Basel (CH), 4 March 2019 – Lonza announced today the adjustment of its Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit and to emphasize Lonza's focus on growth along the Healthcare Continuum®. The adjustment consists of excluding the Water Care Mid-Term Guidance from the Lonza Group financial projections prepared in 2017. The Water Care Mid-Term...

Read More »
Company News

Lonza Achieved Another Excellent Full-Year Result in 2018 with 9% Organic Sales Growth and Strong Profitability Driven by Healthcare Businesses

Lonza delivered its Full-Year 2018 results with sales of CHF 5.5 billion at a record 27.3% CORE EBITDA margin for Lonza’s continuing operations Outperformance in Pharma & Biotech with 14% sales growth and margins up 260 bps was combined with positive momentum in the Consumer Health division Lonza continued to benefit from the performance and synergies of the successfully integrated Capsugel...

Read More »
Company News

Lonza to Establish Strategic Biomanufacturing Base in China Using GE Healthcare Solution

New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities from early- to late-clinical and early-commercial stages GE Healthcare’s off-the-shelf biologics factory, KUBio, will provide the base for GMP manufacturing Memorandum of understanding to be signed with Guangzhou Development District for leasing of the 17,000m2 site Basel (CH) and...

Read More »
Company News

Lonza Further Strengthens Focus on Its Healthcare Continuum Strategy by Signing Agreement to Divest Water Care Business to Platinum Equity

Basel (CH) and Los Angeles, CA (USA), 1 November 2018 – Lonza and Platinum Equity jointly announced today that Platinum Equity has entered into a definitive agreement with Lonza to acquire Lonza's Water Care business and operations for USD 630 million. The inclusion of the French business in this transaction is still under discussion. With headquarters in Alpharetta, GA (USA), Water Care...

Read More »
Mergers & Acquisitions

Lonza Acquires a Controlling Stake in Octane Biotech to Further Develop Cocoon™ Autologous Technology

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies  Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support...

Read More »

All Topics

COVID-19 Response Suppliers COVID-19 Response:
Can Your Company Help Provide Critical Supplies?

We are using the power of our platform to aid in the mass shortage of critical supplies. If your company can help provide supplies, capabilities, or materials for products such as N-95 Masks and Tyvek SuitsPlease let us know.

COVID-19 Response Suppliers